Synonyms: (4R,5S,6S)-pivaloyloxymethyl 3-(1-(4,5-dihydrothiazol-2-yl)azetidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; L 084; L-084; L084; ME1211; SPR 994; SPR-994; SPR994; TBM-PI; Tebi-pivoxil; [4R-[4a,5ß,6ß(R*)]]-3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester
Molecular Formula: C22H31N3O6S2
Molecular Weight: 497.63
Linear Structural Formula: C22H31N3O6S2
MDL Number: MFCD17215369
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: Tebipenem pivoxil (L-084I; ME1211; SPR994; Tebi-pivoxil; TBM-PI) corresponds to the orally bioavailable pivalyl ester prodrug form of the carbapenem class broad-spectrum beta-lactam antibiotic Tebipenem (LJC 11,036; SPR859; TBM). TBM is potent against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many beta-lactamase-producing strains, while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa. TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections.